title: Commentary: Does additional benefit justify additional costs of insulin analogues?
authors.affiliation: Institute for Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany. peter.sawicki@uk-koeln.de
authors.forename: Peter T
authors.initials: PT
authors.lastname: Sawicki
mesh_terms: D003362:Cost-Benefit Analysis; D003920:Diabetes Mellitus / Q000188:drug therapy; D016527:Drug Costs; D004345:Drug Industry; D005858:Germany; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin